Literature DB >> 25997172

Differences in early speech patterns between Parkinson variant of multiple system atrophy and Parkinson's disease.

Young Eun Huh1, Jongkyu Park1, Mee Kyung Suh2, Sang Eun Lee3, Jumin Kim1, Yuri Jeong4, Hee-Tae Kim5, Jin Whan Cho6.   

Abstract

In Parkinson variant of multiple system atrophy (MSA-P), patterns of early speech impairment and their distinguishing features from Parkinson's disease (PD) require further exploration. Here, we compared speech data among patients with early-stage MSA-P, PD, and healthy subjects using quantitative acoustic and perceptual analyses. Variables were analyzed for men and women in view of gender-specific features of speech. Acoustic analysis revealed that male patients with MSA-P exhibited more profound speech abnormalities than those with PD, regarding increased voice pitch, prolonged pause time, and reduced speech rate. This might be due to widespread pathology of MSA-P in nigrostriatal or extra-striatal structures related to speech production. Although several perceptual measures were mildly impaired in MSA-P and PD patients, none of these parameters showed a significant difference between patient groups. Detailed speech analysis using acoustic measures may help distinguish between MSA-P and PD early in the disease process.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acoustic analysis; Multiple system atrophy; Parkinson’s disease; Perceptual analysis; Speech

Mesh:

Year:  2015        PMID: 25997172     DOI: 10.1016/j.bandl.2015.04.007

Source DB:  PubMed          Journal:  Brain Lang        ISSN: 0093-934X            Impact factor:   2.381


  8 in total

1.  Speech-based characterization of dopamine replacement therapy in people with Parkinson's disease.

Authors:  R Norel; C Agurto; S Heisig; J J Rice; H Zhang; R Ostrand; P W Wacnik; B K Ho; V L Ramos; G A Cecchi
Journal:  NPJ Parkinsons Dis       Date:  2020-06-12

Review 2.  Speech disorders in Parkinson's disease: early diagnostics and effects of medication and brain stimulation.

Authors:  L Brabenec; J Mekyska; Z Galaz; Irena Rektorova
Journal:  J Neural Transm (Vienna)       Date:  2017-01-18       Impact factor: 3.575

3.  Automated Detection of Speech Timing Alterations in Autopsy-Confirmed Nonfluent/Agrammatic Variant Primary Progressive Aphasia.

Authors:  Adolfo M García; Ariane E Welch; Maria Luisa Mandelli; Maya L Henry; Sladjana Lukic; María José Torres Prioris; Jessica Deleon; Buddhika M Ratnasiri; Diego L Lorca-Puls; Bruce L Miller; William Seeley; Adam P Vogel; Maria Luisa Gorno-Tempini
Journal:  Neurology       Date:  2022-05-27       Impact factor: 11.800

4.  Vocal changes in a zebra finch model of Parkinson's disease characterized by alpha-synuclein overexpression in the song-dedicated anterior forebrain pathway.

Authors:  Cesar A Medina; Eddie Vargas; Stephanie J Munger; Julie E Miller
Journal:  PLoS One       Date:  2022-05-04       Impact factor: 3.752

5.  Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy.

Authors:  Jan Rusz; Tereza Tykalová; Giulio Salerno; Serena Bancone; Johara Scarpelli; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2019-03-11       Impact factor: 4.849

6.  The analysis of relationship between selected sociodemografic factors and disorders of speech organs in Parkinson`s patients.

Authors:  Wioletta Pawlukowska; Karolina Skonieczna-Żydecka; Iwona Rotter; Krystyna Honczarenko; Przemysław Nowacki
Journal:  BMC Neurol       Date:  2017-12-21       Impact factor: 2.474

7.  Speech-based characterization of dopamine replacement therapy in people with Parkinson's disease.

Authors:  R Norel; C Agurto; S Heisig; J J Rice; H Zhang; R Ostrand; P W Wacnik; B K Ho; V L Ramos; G A Cecchi
Journal:  NPJ Parkinsons Dis       Date:  2020-06-12

8.  Parkinson's disease or atypical parkinsonism? The importance of acoustic voice analysis in differential diagnosis of speech disorders.

Authors:  Renata Kowalska-Taczanowska; Andrzej Friedman; Dariusz Koziorowski
Journal:  Brain Behav       Date:  2020-06-11       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.